Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing innovative therapeutic solutions for patients suffering from serious neurology-mediated conditions. The company is primarily focused on the development and commercialization of Haduvio, a novel treatment aimed at addressing unmet medical needs in this therapeutic area. Based in New Haven, Connecticut, Trevi is positioned to leverage its expertise in neurology and drug development as it progresses through clinical trials and prepares for potential market entry.